References
- AgidYDuboisBAnandREfficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer typeCurr Ther Res Clin Exp19985983745
- BallardCGAdvances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibitionEur Neurol200247647011803198
- BartusRTDeanRL3BeerBThe cholinergic hypothesis of geriatric memory dysfunctionScience1982217408147046051
- BirksJGrimley EvansJIakovidouVRivastigmine for Alzheimer’s disease (Cochrane Review)The Cochrane Library, Issue 32002OxfordUpdate Software
- BirksJCholinesterase inhibitors for Alzheimer’s diseaseCochrane Database of Systematic Reviews2006Issue 1 Art. No.: CD005593. DOI:10.1002/14651858.CD005593
- BorroniBColciaghiFPastorinoLAmyloid precursor protein in platelets of patients with Alzheimer’s disease: effect of acetylcholinesterase inhibitor treatmentArch Neurol200158442811255448
- BullockRDengizACognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitor for up to 5 yearsInt J Clin Pract2005598172215963209
- BullockRTouchonJBergmanHRivastigmine and donepezil treatment in moderate to moderately severe Alzheimer’s disease over a 2-year periodCurr Med Res Opin20052113172716083542
- CaltagironeCBianchettiADi LucaMItalian Association of Psychogeriatrics. 2005Guidelines for the treatment of Alzheimer’s disease from the Italian Association of PsychogeriatricsDrugs Aging200522Suppl 112616506439
- Corey-BloomJAnandReachJV. for the ENA 713 B352 Study Group. 1998A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Geriatr Psychopharmacol199815565
- CummingsJLCholinesterase inhibitors: A new class of psychotropic compoundsAm J Psychiatry200015741510618007
- DantoineTAuriacombeSSarazinMRivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatmentInt J Clin Pract200660110816409439
- DaviesKLMaloneyAJSelective loss of central cholinergic neurons in Alzheimer’s diseaseLancet19762140363862
- DejongROsterlundOWRoyGWMeasurement of quality of life changes in patients with Alzheimer’s diseaseClin Ther198911545542776169
- DoodyRSStevensJCBeckCPractice parameter: management of dementia (an evidence based review). Report of the quality standards subcommittee of the American Academy of NeurologyNeurology20015611546611342679
- FarlowMAnandRMessinaJA 52-week study of the efficacy of rivastigmine in patients with mild-to-moderate severe Alzheimer’s diseaseEur Neurol2000442364111096224
- FerriCPPrinceMBrayneCGlobal prevalence of dementia: a Delphi consensus studyLancet20053662112716360788
- FolsteinMFFolsteinSEMini Mental State: a practical method for grading the cognitive state of patients for the cliniciansJ Psychiatr Res197512189981202204
- ForetteFAnandRGharabawiGA phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of Rivastigmine (Exeloninfinity)Eur J Neurol19996423910362894
- FuschilloCLa PiaSCampanaFCognitive deficits in Alzheimer’s disease: treatment with acetylcholinesterase inhibitor agentsArch Gerontol Geriatr200171518
- GallagherMColomboPJAgeing: The cholinergic hypothesis of cognitive declineCurr Opin Neurobiol1995516187620303
- GauthierSJubyAMorelliLA large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND StudyCurr Med Res Opin20062222516517076986
- GiacobiniEDunitzLondon M.Cholinesterase inhibitors: from the calabar bean to Alzheimer therapyCholinesterases and cholinesterase inhibitors: from molecular biology to therapy2000181226
- GrossbergGTStahelinHBMessinaJCLack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medicationsInt J Geriatr Psychiatry200015242710713582
- GrossbergGIrwinPSatlinARivastigmine in Alzheimer’s disease: efficacy over two yearsAm J Geriatr Psychiatry2004124203115249280
- KasaPRakonczayZGulyaKThe cholinergic system in Alzheimer’s diseaseProg Neurobiol199752511359316159
- KatzmanRAlzheimer’s diseaseN Engl J Med1986314964732870433
- LanctôtKLHerrmannNYauKKEfficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysisCMAJ20031695576412975222
- LawtonMPBrodyEMAssessment of older people: self-maintaining and instrumental activities of daily livingGerontologist19699179865349366
- LovemanEGreenCKirbyJThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s diseaseHealth Technol Assess200610000000
- McKhannGDrachmanDClinical diagnosis of Alzheimer’s disease: report of the NINCDS ADRDA Work group, Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology198434939446610841
- MingerSLEsiriNMMcDonaldBCholinergic deficits contribute to behavioral disturbance in patients with dementiaNeurology2000551460711094098
- O’BrianJTBallardCGDrugs for Alzheimer’s diseaseBMJ2001323123411463665
- ReisbergBSchneiderLDoodyRClinical global measure of dementia: position paper from the International Working Group on Harmonization of Dementia Drug GuidelinesAlzheimer Dis Assoc Disord199711Suppl 38189305508
- RosenWGMohsRDavisKA new rating scale for Alzheimer’s diseaseAm J Psychiatry19841411356646496779
- RoslerMAnandRCicin-SainAEfficacy and safety of rivastigmine in patients with Alzheimer disease: international randomised controlled trialBMJ19993186334010066203
- SchneiderLSOlinJTDoodyRSValiability and reliability of the Alzheimer’s disease Cooperative Study – Clinical Global ChangeAlzheimer Dis Assoc Disord19971Suppl 2S22329236949
- SchneiderLSThe post-modern world of Alzheimer’s disease trials: how much is an ADAS-cog point worth in central London?Int J Geriatr Psychiatry20062191316353164
- SmallGKauferKMendiondoMSCognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 yearsInt J Clin Pract200559473715853867
- SpiegelRBrunnerCErmini-FunfschillingDA new behavioural assessment scale for geriatric out-and in-patients: the NOSGER (Nurses’ Observation Scale for Geriatric Patients)J Am Geriatr Soc199139339472010583
- TaskerAPerryEKBallardGCButyrrilcholinesterase: impact on symptoms and progression of cognitive impairmentExpert Rev Neurother20055101615853480
- [NICE] The National Institute of Clinical ExcellenceThe National Institute of Clinical Excellence (NICE) approves drugs for Alzheimer’s diseaseBMJ2001190322
- WeinstockMSelectivity of cholinesterase inhibitionCNS Drugs19991230723
- WhitehousePJPriceDLStrubleRGAlzheimer’s disease and senile dementia: Loss of neurons in the basal forebrainScience1982215123797058341
- WilkinsonDGPassmoreAPBullockRA multinational, randomised, 12-week, comparative study of donepezil and rivastig-mine in patients with mild to moderate Alzheimer’s diseaseInt J Clin Pract200256441612166542
- WilliamsBRNazariansAGillMAA review of rivastigmine: a reversible cholinesterase inhibitorClin Ther200325163412860489